EEF1A2 and breast carcinoma: The STn antigen has been investigated widely as a circulating biomarker for numerous cancer types [17], and a vaccine against STn has been tested in clinical trials and can increase survival in a subset of breast cancer patients receiving hormonal therapy [56,57,58].